|
|
|
|
|
by A_D_E_P_T
21 days ago
|
|
Proving "efficacy" -- which is the difficult and expensive part -- should not be necessary, and the government increasingly moves its own goalposts as to what the word efficacy even means. Simple as that. Postmarketing surveillance can easily determine what's effective and what's not, and medical orgs can adjust. |
|
This is especially great because it puts anyone who actually wants to actually make a working drug at a significant disadvantage. It'll take them longer to get to market, cost them a billion dollars more, then their medicine gets to sit next to a thousand variations of "Vitamin C for Leukemia" that all cost a lot less.
There would be virtually no incentive for anyone to make an actual drug.
> Postmarketing surveillance can easily determine what's effective and what's not, and medical orgs can adjust.
"Easily" is doing a ton of work. Postmarketing surveillance can sometimes give low-confidence signal as to what's effective and what's not.